| Literature DB >> 20971733 |
Keren Borensztajn1, Paul Bresser, Chris van der Loos, Ilze Bot, Bernt van den Blink, Michael A den Bakker, Joost Daalhuisen, Angelique P Groot, Maikel P Peppelenbosch, Jan H von der Thüsen, C Arnold Spek.
Abstract
Idiopathic pulmonary fibrosis constitutes the most devastating form of fibrotic lung disorders and remains refractory to current therapies. The coagulation cascade is frequently activated during pulmonary fibrosis, but this observation has so far resisted a mechanistic explanation. Recent data suggest that protease-activated receptor (PAR)-2, a receptor activated by (among others) coagulation factor (F)Xa, plays a key role in fibrotic disease; consequently, we assessed the role of PAR-2 in the development of pulmonary fibrosis in this study. We show that PAR-2 is up-regulated in the lungs of patients with idiopathic pulmonary fibrosis and that bronchoalveolar lavage fluid from these patients displays increased procoagulant activity that triggers fibroblast survival. Using a bleomycin model of pulmonary fibrosis, we show that bleomycin induces PAR-2 expression, as well as both myofibroblast differentiation and collagen synthesis. In PAR-2-/- mice, both the extent and severity of fibrotic lesions are reduced, whereas myofibroblast differentiation is diminished and collagen expression is decreased. Moreover, fibrin deposition in the lungs of fibrotic PAR-2-/- mice is reduced compared with wild-type mice due to differential tissue factor expression in response to bleomycin. Taken together, these results suggest an important role for PAR-2 in the development of pulmonary fibrosis, and the inhibition of the PAR-2-coagulation axis may provide a novel therapeutic approach to treat this devastating disease.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20971733 PMCID: PMC2993271 DOI: 10.2353/ajpath.2010.091107
Source DB: PubMed Journal: Am J Pathol ISSN: 0002-9440 Impact factor: 4.307